

PRESS RELEASE – FOR IMMEDIATE RELEASE

## IntegraGen – 2013 revenues up 15% at 5.45 M€

**EVRY, FRANCE, JANUARY 21, 2014** - **IntegraGen**, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced its revenues for year ending December 31st, 2013.

2013 revenues were of € 5.45 million, a growth of 15% compared to 2012

<i>in Thousand €</i>	<b>2013</b>	<b>2012</b>	<b>Var. (%)</b>
<b>Revenues</b>	<b>5 454</b>	<b>4 748</b>	<b>+15%</b>

### Significant growth of Genomic services

Sequencing services continue to represent the largest part of the genomic services. This strong and continued revenue growth confirms IntegraGen’s ability to provide business and academic research laboratories with services that are highly efficient and at the forefront of innovation. As a result of sequencing more than 2,300 exomes and contracting 220 genomic projects for over 150 customers in 2013, IntegraGen continues to reinforce its leadership in the field.

### Developing sales of ARISK<sup>®</sup> Test, the genetic risk assessment test for autism in the USA

Revenues from sales of the ARISK<sup>®</sup> Test reached \$55 k in 2013. IntegraGen noted that most physicians who prescribe the test do so for more than one child in their practice. The Company has also been successful in obtaining reimbursement for the test from a number of private medical insurance companies. The Company looks to grow test revenue in 2014 even though 2013 test volume was modest.

IntegraGen also announces the release of the ARISK 2<sup>®</sup> Test in late 2013 which broadens the eligible population for the test to now include the evaluation of the autism risk to children presenting with signs of developmental delay, regardless of their family history with autism. This second generation version of the ARISK<sup>®</sup> Test, which addresses a market twenty times larger than that the initial version of the test, has been enthusiastically anticipated by current prescribers.

***IntegraGen will publish its annual results in April 2014.***

### ABOUT INTEGRAGEN

Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests in the fields of autism and oncology. IntegraGen’s mission is to translate molecular research into clinical practice through the identification of novel genetic biomarkers and the subsequent development of molecular diagnostic tests which allow clinicians to better manage the clinical care of their patients. IntegraGen is also a leader in delivering expert genomic service solutions to academic researchers and life sciences companies as a result of its scientific knowledge and technological expertise related to cutting edge genomic platforms and bioinformatics.

For more information on IntegraGen visit [www.integragen.com](http://www.integragen.com)

## CONTACTS



### INTEGRAGEN

Bernard COURTIEU  
CEO

Laurence RIOT LAMOTTE  
CFO

[contact@integragen.com](mailto:contact@integragen.com)

Tel.: +33 (0)1 60 91 09 00

### NEWCAP.

#### Investor and Media relations

Emmanuel HUYNH  
Louis-Victor DELOUVRIER

[integragen@newcap.fr](mailto:integragen@newcap.fr)

Tel.: +33 (0)1 44 71 94 94